StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Eisai Co., Ltd. (Lenvima Oncology Alliance) by Quarter

Eisai Co., Ltd. (Lenvima Oncology Alliance) — Net R&D cost-sharing expense ($M) ($M)

QuarterlyAnnual

Merck Eisai Co., Ltd. (Lenvima Oncology Alliance): $0M in Q2 2026, down 100.0% from a year earlier. That is the lowest of the 34 quarters on record here.

Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
-100.0%
3 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
29
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-07) ↗

Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEisai Co., Ltd. (Lenvima Oncology Alliance) — Net R&D cost-sharing expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20260-100.0%Form 10-Q (filed 2026-08-07) ↗
Q1 2026Mar 31, 20262-60.0%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 20251-66.7%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 20252-50.0%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 20253-50.0%Form 10-Q (filed 2026-08-07) ↗
Q1 2025Mar 31, 20255-37.5%Form 10-Q (filed 2026-05-04) ↗
Q4 2024Dec 31, 20243-40.0%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 20244-20.0%Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 20246-64.7%Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 20248-79.5%Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 20235-37.5%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 20235-79.2%Form 10-Q (filed 2024-11-06) ↗
Q2 2023Jun 30, 202317-63.8%Form 10-Q (filed 2024-08-05) ↗
Q1 2023Mar 31, 202339-31.6%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 202280.0%Form 10-K (filed 2025-02-25) ↗
Q3 2022Sep 30, 202224-44.2%Form 10-Q (filed 2023-11-03) ↗

Cite this data

StockData. (2026). Merck Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-eisai-rd

See every metric in the Merck KPI table. Data updated Oct 26, 2026.